GLP-1 maintenance dosing: what the evidence says about keeping weight off

What's this video probably claiming?

Based on the caption and hashtag context, this creator, who identifies as a charge nurse and patient advocate, is likely walking through what a GLP-1 "maintenance phase" looks like in practice. That probably means discussing dose reduction strategies after hitting a weight loss goal, whether staying on a lower dose indefinitely is effective, and whether titrating down or pausing the medication leads to weight regain. Given the framing around "prevention of weight gain after loss," the video almost certainly positions long-term, lower-dose GLP-1 use as a viable maintenance strategy. That's not an unreasonable framing, but the nuance matters enormously here. The clinical picture is messier than most TikTok explainers suggest, and a charge nurse's clinical experience, while valuable, is not a substitute for controlled trial data on maintenance dosing outcomes.

What does the science actually show?

The maintenance data on GLP-1 receptor agonists is pretty sobering if you read it carefully. The STEP 1 Extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed semaglutide 2.4 mg patients after they stopped treatment. Within one year of discontinuation, participants regained approximately two-thirds of their prior weight loss. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) addressed maintenance more directly: patients who continued tirzepatide 10 mg or 15 mg after an initial 36-week loss phase maintained weight loss and lost an additional 5.5% body weight over 52 weeks, while those switched to placebo regained 14% of their body weight. This is the clearest signal yet that continuing the drug, not stopping it, is what drives maintenance. A lower maintenance dose is biologically plausible but not yet robustly validated in large trials. The GLP-1 mechanism works by suppressing appetite via hypothalamic pathways and slowing gastric emptying; when the drug leaves the system, those effects reverse.

Where does the social media noise diverge from clinical reality?

The divergence is significant and worth naming directly. TikTok content in the GLP-1 space tends to frame maintenance dosing as a straightforward "dial it down" strategy, as if the body simply holds its new set point once you lose the weight. That is not what the biology shows. GLP-1 receptors do not appear to recalibrate permanently after a treatment course. More importantly, "maintenance dose" is not a standardized clinical term in the GLP-1 literature. Wegovy's approved maintenance dose for semaglutide is 2.4 mg weekly after a 16 to 20 week titration. There is no FDA-approved lower maintenance dose for weight. Creators suggesting patients can taper to, say, 0.5 mg or 1 mg and maintain results are extrapolating from anecdote, not controlled data. There is also a real risk that content framing this as accessible self-management discourages patients from having honest conversations with prescribers about whether staying on full therapeutic doses long-term is medically appropriate for them.

What should you actually know?

Long-term GLP-1 use for weight maintenance is increasingly supported by trial data, but the evidence points toward staying on therapeutic doses, not tapering off them. If you have reached your weight goal on a GLP-1 and are wondering what comes next, that is a legitimate clinical question, but the answer depends on your metabolic history, cardiovascular risk profile, and cost and access situation. The SELECT trial (Lincoff et al., 2023, NEJM) showed cardiovascular mortality benefits of semaglutide 2.4 mg in patients with overweight or obesity and established cardiovascular disease, which adds another layer to the calculus beyond just the number on the scale. Insurance coverage for long-term use remains a serious structural barrier. Content that frames maintenance as simple or self-directable does a disservice to patients navigating a genuinely complicated decision. Talk to your prescriber. Not TikTok.